Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis
High Omalizumab dose, administered at strictly 30-day intervals, controls venom immunotherapy reactions in systemic mastocytosis.
*Chief Allergology Department
8 Fidippidou st. Athens 11526
Tel.: +30 2107774666; ++30 6932421516
Fax: +30 2106010842
No abstract is available for this article.